Oncology

Latest News

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

By Laura Joszt, MA
Eileen Peng, PharmD

May 21st 2025

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

By Pearl Steinzor

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Vandana Abramson, MD, Addresses Treatment Strategies for Metastatic Breast Cancer

May 6th 2013

Vandana Abramson, MD, Addresses Treatment Strategies for Metastatic Breast Cancer

In this video, Vandana Abramson, MD, assistant professor of medicine, Division of Hematology/Oncology, Vanderbilt University, Nashville, TN, discusses the various strategies utilized in the treatment of metastatic breast cancer.

Vandana Abramson, MD, Addresses Treatment Strategies for Metastatic Breast Cancer

May 3rd 2013

Vandana Abramson, MD, Addresses Treatment Strategies for Metastatic Breast Cancer

In this video, Vandana Abramson, MD, assistant professor of medicine, Division of Hematology/Oncology, Vanderbilt University, Nashville, TN, discusses the various strategies utilized in the treatment of metastatic breast cancer.

Martin Edelman, MD, Talks About Improving Outcomes in the Management of NSCLC

May 2nd 2013

Martin Edelman, MD, Talks About Improving Outcomes in the Management of NSCLC

Martin Edelman, MD, Greenbaum Cancer Center, Baltimore, MD, says that organizations like NCCN and ASCO have guidelines for the management of non-small cell lung cancer (NSCLC).

April 16th 2013

More Comprehensive Discussion of CRC Screening Associated With Higher Screening

David M. Mosen, PhD, MPH Adrianne C. Feldstein, MD, MS Nancy A. Perrin, PhD A. Gabriela Rosales, MS David H. Smith, RPh, PhD Elizabeth G. Liles, MD Jennifer L. Schneider, MPH Ronald E. Myers, PhD Jennifer Elston Lafata, PhD

More comprehensive discussion of colorectal screening by primary care physicians was associated with higher screening rates among adults aged 51 to 80 years who were overdue for screening.

March 13th 2013

Multilevel Predictors of Colorectal Cancer Screening Use in California

Salma Shariff-Marco, PhD, MPH Nancy Breen, PhD David G. Stinchcomb, MS, MA Carrie N. Klabunde, PhD

We studied contextual factors and found that locality, availability of primary care, and HMO membership influenced use of colorectal cancer screening in California.

March 13th 2013

Difference In What Medicare Spends On Cancer Care May Not Affect Survival Rates

February 28th 2013

AVEO Oncology: FDA Panel To Review Tivozanib For Treatment Of Advanced RCC

Ira Klein, MD, Discusses Quality Measures in Oncology

February 27th 2013

Ira Klein, MD, Discusses Quality Measures in Oncology

Ira Klein, MD, MBA, FACP, chief medical officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology.

February 26th 2013

Literature Review: Melanoma

February 26th 2013

Crossroads in Breast Cancer: The Intersection of Clinical Uncertainty and Molecular Profiling

Kim Farina, PhD

February 26th 2013

ASH Conference Coverage

February 26th 2013

Partial Fill Strategies for Oral Oncolytics to Reduce Waste and Drive Persistency

Atheer A. Kaddis, PharmD

February 26th 2013

From Bench to Bedside: Promising Colon Cancer Clinical Trials

Jill M. Comeau, PharmD, BCOP Brice Labruzzo Mohundro, PharmD, BCACP

February 26th 2013

The Future of Oncology? COME HOME, the Oncology Medical Home

Barbara L. McAneny, MD

February 26th 2013

Focusing on Clinical and Economic Outcomes-Not Guidelines

Is It Time for a New Direction in Oncology Care?

Interview With Andrew Pecora, MD, CPE, President, Regional Cancer Care Associates, Chief Innovations Officer and Vice President, Cancer Services, John Theurer Cancer Center at Hackensack University Medical Center

February 26th 2013

The Role of Companion Diagnostic Testing in Payer Decision Making

February 26th 2013

Literature Review: Chronic Myeloid Leukemia

February 25th 2013

Lessons From an Oncology Medical Home Collaborative

John Fox, MD, MHA

February 22nd 2013

FDA Approves New Treatment for Late-Stage Breast Cancer

February 19th 2013

Cancer Rehab Begins To Bridge A Gap For Patients

February 18th 2013

The Growing Cost of Specialty Pharmacy-Is it Sustainable?

We only have to take a brief look back to see that 10 years ago, most specialty drugs were injectable agents used to treat conditions such as rheumatoid arthritis, multiple sclerosis, and growth disorders. Today, the list of agents that is considered specialty includes many oral drugs and even some inhaled agents. In just more than 2 decades, the specialty drug market place has grown substantially.

February 13th 2013

Short-Term Costs Associated With Primary Prophylactic G-CSF Use During Chemotherapy

Suja S. Rajan, MHA, MS, PhD William R. Carpenter, MHA, PhD Sally C. Stearns, PhD Gary H. Lyman, MD, MPH

Granulocyte colony-stimulating factor therapy reduces hospitalizations and improves chemotherapy administration in elderly breast cancer patients, but increases overall Medicare costs during first year of therapy.

January 30th 2013

Abraxane Capitalizes on the Resurgence of Chemotherapy Combinations in Pancreatic Cancer at ASCO GI 2013

January 29th 2013

Less is More? New Study Indicates Less Invasive Treatment May Yield Better Results for Breast Cancer Patients

Bruce Feinberg, DO, Speaks About Clinical Pathways in Oncology Care

January 24th 2013

Bruce Feinberg, DO, Speaks About Clinical Pathways in Oncology Care

Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, says that there is a tremendous amount of waste in the system.

Darius Lakdawalla, PhD, Discusses the Payer/Provider Relationship in Oncology Management

January 22nd 2013

Darius Lakdawalla, PhD, Discusses the Payer/Provider Relationship in Oncology Management

Darius Lakdawalla, PhD, Director of Research, Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, thinks that payers follow the lead of providers in oncology management.

January 21st 2013

Revisiting the Integrated Delivery Network Model

The idea behind an integrated delivery network (IDN)-a concept that was developed in the 1980s and widely implemented in the 1990s-is that a network of facilities and providers can work together to offer a continuum of care in a particular geographic area. Although the concept was one that initially drew praise, the implementation of this type of system did not gain momentum from the onset. However, as time has elapsed, advancements have made this model worth revisiting.

January 21st 2013

New Pump a 'Game-Changer' for Cancer Patients

January 16th 2013

500,000 Women to be Offered Breast Cancer Drugs

Jan Berger, MD, MJ, Addresses Challenges in Oncology Management

January 15th 2013

Jan Berger, MD, MJ, Addresses Challenges in Oncology Management

"Oncology is a very emotional area," says Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners, Editor-in-Chief, The American Journal of Pharmacy Benefits.

...

173 174 175 176 177 178 179 180 181

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions